EntryPoint Capital LLC Takes $294,000 Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

EntryPoint Capital LLC acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 8,167 shares of the medical device company’s stock, valued at approximately $294,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. boosted its position in shares of Tandem Diabetes Care by 17.6% during the third quarter. Advisors Asset Management Inc. now owns 10,200 shares of the medical device company’s stock worth $433,000 after buying an additional 1,525 shares during the period. Intech Investment Management LLC lifted its stake in Tandem Diabetes Care by 156.0% during the 3rd quarter. Intech Investment Management LLC now owns 18,336 shares of the medical device company’s stock worth $778,000 after acquiring an additional 11,173 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Tandem Diabetes Care by 3.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 586,063 shares of the medical device company’s stock valued at $24,855,000 after acquiring an additional 18,874 shares during the period. Cerity Partners LLC increased its stake in Tandem Diabetes Care by 21.8% during the third quarter. Cerity Partners LLC now owns 62,796 shares of the medical device company’s stock worth $2,663,000 after purchasing an additional 11,247 shares during the period. Finally, Brooklyn Investment Group purchased a new stake in Tandem Diabetes Care during the third quarter worth about $28,000.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, with a total value of $190,948.56. Following the acquisition, the chief operating officer now directly owns 10,538 shares of the company’s stock, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 2.20% of the company’s stock.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM opened at $19.81 on Friday. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -10.26 and a beta of 1.45. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32. Tandem Diabetes Care, Inc. has a 1-year low of $17.64 and a 1-year high of $53.69. The firm’s fifty day moving average price is $28.40 and its 200 day moving average price is $33.25.

Wall Street Analysts Forecast Growth

TNDM has been the subject of a number of research reports. Barclays dropped their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $35.00 to $25.00 in a research note on Friday, February 28th. Robert W. Baird cut their price objective on Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating on the stock in a research report on Thursday, February 27th. Wells Fargo & Company reiterated an “equal weight” rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a report on Monday, March 3rd. Finally, Royal Bank of Canada reduced their price target on Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.38.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.